The role of site-specific therapy for cancers of unknown of primary: A meta-analysis
| Autor: | Ziad Bakouny, Eliezer M. Van Allen, Elie El Rassy, Karim Fizazi, F. Anthony Greco, Toni K. Choueiri, Nicholas Pavlidis |
|---|---|
| Přispěvatelé: | Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Département de médecine oncologique [Gustave Roussy], Dana-Farber Cancer Institute [Boston], University of Ioannina |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty [SDV]Life Sciences [q-bio] MEDLINE 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Humans Progression-free survival Prospective cohort study ComputingMilieux_MISCELLANEOUS Clinical Oncology Clinical Trials as Topic business.industry Cancer medicine.disease Prognosis Combined Modality Therapy Confidence interval 3. Good health Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Meta-analysis Neoplasms Unknown Primary business Empiric therapy |
| Zdroj: | European Journal of Cancer European Journal of Cancer, Elsevier, 2020, 127, pp.118-122. ⟨10.1016/j.ejca.2019.12.016⟩ |
| ISSN: | 0959-8049 |
| Popis: | Cancers of unknown primary (CUP) are among the most common causes of death due to cancer, are associated with a poor prognosis and have few therapeutic options available. Molecularly-guided site-specific treatments were explored based on the assumption that CUP are similar in their response to treatment of predicted primary tumours. Given the discordant results between these studies, a meta-analysis using a random-effects model and the inverse variance method was performed. MEDLINE and conference abstracts of American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) meetings were searched from inception until November 2019. A trend towards improved OS was noted with site-specific versus empiric treatment for CUP (HR = 0.73; 95% confidence interval (CI) 0.52–1.02). There was significant heterogeneity across the four studies (I [2] = 79%; p = 0.002) but no significant difference was noted between the treatment effect in the two subgroups (randomised vs. non-randomised; p = 0.07). The test for overall effect for progression free survival, which had only been reported for the two randomised studies, was not statistically significant (HR = 0.93; 95% CI 0.74–1.17), with little heterogeneity between studies (I [2] = 0%; p = 0.77). The results of this meta-analysis highlight the significant heterogeneity between the prospective studies comparing molecularly tailored to empiric therapy for CUP and the need for other randomised studies including only primary tumors with available effective therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect